Skip to main content

Phenylephrine Sales Sizeable and Steady Despite Efficacy Concerns

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 13, 2024.

By Lori Solomon HealthDay Reporter

TUESDAY, Feb. 13, 2024 -- Despite concerns about clinical efficacy, phenylephrine was the most common oral decongestant sold in the United States from 2012 to 2021, according to a research letter published online Feb. 8 in the Journal of the American Medical Association.

Timothy S. Anderson, M.D., from the University of Pittsburgh, and colleagues examined patterns of the purchasing of oral decongestants as a drug class based on U.S. data from the IQVIA Multinational Integrated Data Analysis quarterly pharmaceutical sales volume (units; 2012 to 2021).

The researchers found there were 732 unique phenylephrine products (21 standalone and 711 combination products) and 495 pseudoephedrine products (54 standalone and 441 combination products). During the study period, there were 19.8 billion units of phenylephrine products purchased, amounting to $3.4 billion in pharmacy expenditures, and 13.2 billion units of pseudoephedrine products purchased, amounting to $3.8 billion in pharmacy expenditures. Over all the years, units of phenylephrine purchased outpaced pseudoephedrine, which had significantly declining sales from 1.68 billion units in 2012 to 0.98 billion units in 2021. The vast majority of sales of phenylephrine-containing formulations contained three or more active ingredients (85.5 percent), most commonly analgesics and antitussives.

"The delays between concerns about efficacy of oral phenylephrine being raised and Food and Drug Administration action highlight the need for continued reform of the nonprescription drug review process," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted February 2024

Read this next

Study Addresses Nasal Rinsing and Nonkeratitis Acanthamoeba Infection

MONDAY, March 18, 2024 -- In a report published in the April issue of Emerging Infectious Diseases, the details of 10 cases of nonkeratitis Acanthamoeba infection are described...

Validated COuGH RefleX Score Can Predict Likelihood of GERD

WEDNESDAY, March 6, 2024 -- The validated Cough, Overweight/Obesity, Globus, Hiatal Hernia, Regurgitation, and Male Sex (COuGH RefluX) score can predict the likelihood of proven...

CVS Pulling Popular Cold Meds From Shelves After Report Deems Them to Be Useless

FRIDAY, Oct. 20, 2023 -- CVS Health plans to pull cold medications that contain phenylephrine from its store shelves after federal regulators determined recently that the...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.